[A new treatment for osteoporosis using fully human monoclonal antibody to RANKL, AMG 162].

Keywords

RANKL, Bone mineral, Osteoporosis, Bone resorption, Monoclonal antibody

References

No references recorded for this paper.

Cited by

• The cellular and molecular biology of periprosthetic osteolysis.P. Edward Purdue, Panagiotis Koulouvaris, Hollis G. Potter — 2007
• The Central Role of Wear Debris in Periprosthetic OsteolysisP. Edward Purdue, Panagiotis Koulouvaris, Bryan J. Nestor — 2006
• RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases modelKathleen M. Woods Ignatoski, June Escara‐Wilke, Jiang’an Dai — 2008
• Therapeutic intervention for wear debris-induced aseptic implant looseningKe Ren, Anand Dusad, Yijia Zhang — 2013
• RANKLInhibition Is an EffectiveAdjuvant for Docetaxelin a ProstateCancerBone MetastasesModelM. W. Ignatoski, J. Escara-Wilke, Jinlu Dai — 2008

Related papers

• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibodyDesmond Padhi, Graham Jang, Brian Stouch — 2011
• Denosumab (AMG 162) Inhibition of Rank Ligand Increases Bone Mineral Density After Two Years of Treatment in Postmenopausal Women with Low Bone Mineral DensityE. Michael Lewiecki, Paul D. Miller, Michael R. McClung — 2006
• Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor &kgr;B in women with postmenopausal osteoporosisRebeca Reyes‐García, Manuel Muñoz‐Torres, Diego Fernández García — 2010
• Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.Simona D’Amore, Margherita Fanelli, Simona D’Amore — 2006
• Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapyLaia Gifre, Sílvia Ruiz-Gaspà, Josep L. Carrasco — 2017
• Vitamin D, OPG/RANKL, and Inflammation with Alendronate Treatment in HIV-infected Patients with Reduced Bone Mineral DensityJavzandulam Natsag, MA Kendall, DEBORAH E. SELLMEYER — 2015
• Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption markerY. Mori, Hidefumi Kasai, Atsushi Ose — 2018
• Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.Giuseppe Martini, Luigi Gennari, Daniela Merlotti — 2007
• Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.Lorenz C. Hofbauer, Ute Zeitz, Michael Schoppet — 2009